[Use of levosimendan after cardiac arrest by ventricular fibrillation: a case report]

Clin Ter. 2005 May-Jun;156(3):111-4.
[Article in Italian]

Abstract

We describe the case of a patient admitted in intensive care, after cardiac arrest by ventricular fibrillation treated by electrical defibrillation, that showed a serious deficit of the cardiac index and increase of the systemic vascular resistances. The patient was treated by levosimendan (Simdax): a starter dose of 12 microg/Kg in ten minutes and then a continuous perfusion of 0.1 microg/Kg/min. for 24 hours. He had a continuous amelioration of the clinical conditions and of the hemodynamics parameters. In the fifth day the patient was transferred to the Cardiology department and after 20 days he was discharged from hospital.

Publication types

  • Case Reports

MeSH terms

  • Anti-Arrhythmia Agents / therapeutic use*
  • Critical Care
  • Electric Countershock
  • Electrocardiography
  • Heart Arrest / etiology*
  • Heart Arrest / therapy
  • Humans
  • Hydrazones / therapeutic use*
  • Male
  • Middle Aged
  • Pyridazines / therapeutic use*
  • Simendan
  • Treatment Outcome
  • Ventricular Fibrillation / complications
  • Ventricular Fibrillation / drug therapy*
  • Ventricular Fibrillation / therapy

Substances

  • Anti-Arrhythmia Agents
  • Hydrazones
  • Pyridazines
  • Simendan